Showing 1631-1640 of 2216 results for "".
- Systematic Review Examines Vaginal Laser and Radiofrequency for Stress Urinary Incontinencehttps://modernaesthetics.com/news/systematic-review-examines-vaginal-laser-and-radiofrequency-for-stress-urinary-incontinence/2486518/In a systematic review and meta-analysis published in International Urogynecology Journal, investigators reported that energy-based devices may offer modest short-term symptom improvement for women with stress urinary incontinence compared with sham treatment. David Lukanović, Gee
- Case Report Describes Dual-Phase CL Code for Facial Rejuvenationhttps://modernaesthetics.com/news/case-report-describes-dual-phase-cl-code-for-facial-rejuvenation/2486484/A case report in the April 2026 issue of Journal of Cosmetic Dermatology described a dual-phase injectable approach to facial rejuvenation that combined contour restoration with ligamentous support using a polycaprolactone-based collagen stimulator. The authors termed the method the “CL
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://modernaesthetics.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- AAD 2026: Lumenis Launches triLIFT 2.0 for Combined Muscle and Skin Rejuvenationhttps://modernaesthetics.com/news/lumenis-launches-trilift-20-for-combined-muscle-and-skin-rejuvenation/2486430/Lumenis Be Ltd. announced the commercial launch of triLIFT 2.0, a next-generation platform designed to deliver combined muscle stimulation and skin rejuvenation for facial and body applications. The system integrates Dynamic Muscle Stimulation technology (DMSt) with FibroBoost, aiming to address
- AAD 2026: CO2 Laser Resurfacing Linked to Transient Microbiome Shiftshttps://modernaesthetics.com/news/aad-2026-co2-laser-resurfacing-linked-to-transient-microbiome-shifts/2486399/New findings presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, provide insight into dynamic microbiome changes following ablative CO2 laser resurfacing and their relationship to wound healing. In this monocentric, double-blind, rando
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://modernaesthetics.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://modernaesthetics.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to